13 active not recruiting. 13 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 13 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM ALXN2220 - Amyloid Transthyretin Cardiomyopathy | Phase 2 | Active not recruiting | Neurimmune AG | 35 | 2025-08-28 | 2026-10-07 |
| A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis Teclistamab - AL Amyloidosis | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 30 | 2025-07-02 | 2026-07-20 |
| Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous), Venetoclax, Dexamethasone - Light Chain (AL) Amyloidosis | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 36 | 2024-10-15 | 2026-07-28 |
| Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis NXC-201 CAR-T - Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Nexcella Inc. | 45 | 2024-06-05 | 2026-07-14 |
| A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy Placebo, ALN-APP - Cerebral Amyloid Angiopathy | Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 210 | 2024-05-17 | 2026-10-20 |
| Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA) NACA - Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain | Phase 2 | Active not recruiting | Arctic Therapeutics | 15 | 2024-04-03 | 2026-07-21 |
| A Study of AT-02 in Subjects With Systemic Amyloidosis. AT02 - Amyloidosis; Systemic | Phase 2 | Active not recruiting | Attralus, Inc. | 120 | 2023-09-21 | 2026-05-06 |
| Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) Venetoclax, Dexamethasone Oral - Light Chain (AL) Amyloidosis, CCND1 Translocation | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 36 | 2023-09-07 | 2025-01-22 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis Daratumumab, Cyclophosphamide, Bortezomib - Amyloidosis | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 151 | 2022-03-01 | 2026-11-03 |
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Daratumumab SC, Pomalidomide, Dexamethasone - Amyloid, AL Amyloidosis | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 15 | 2021-04-14 | 2026-02-27 |
| Ixazomib Maintenance Study in Patients With AL Amyloidosis Ixazomib, Dexamethasone - AL Amyloidosis | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2018-08-02 | 2025-12-04 |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis Siltuximab, The M.D. Anderson Symptom Inventory (MDASI) - Multiple Myeloma, AL Amyloidosis | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-12-14 | 2025-11-04 |
Immunoglobulin Light-chain Amyloidosis (7) · Alzheimer Disease (1) · Cerebral Amyloid Angiopathy (1) · Cerebral Amyloid Angiopathy, Familial (1) · Cerebral Hemorrhage (1) · Dementia (1) · Intracranial Hemorrhages (1) · Multiple Myeloma (1) · Proteostasis Deficiencies (1)
Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Proteostasis Deficiencies (12) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Brain Diseases (3) · Cardiovascular Diseases (3) · Central Nervous System Diseases (3) · Nervous System Diseases (3)
Dexamethasone (6) · daratumumab (3) · venetoclax (3) · ixazomib (2) · pomalidomide (2) · Bendamustine Hydrochloride (1) · Bortezomib (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Injections, Subcutaneous (1) · caficrestat (1) · siltuximab (1)
Memorial Sloan Kettering Cancer Center (2) · Peking Union Medical College Hospital (2) · Alnylam Pharmaceuticals (1) · Arctic Therapeutics (1) · Attralus, Inc. (1) · Columbia University (1) · European Myeloma Network B.V. (1) · Janssen Research & Development, LLC (1) · Neurimmune AG (1) · Nexcella Inc. (1) · Weill Medical College of Cornell University (1)
United States (8) · Netherlands (4) · China (3) · France (3) · Germany (3) · Australia (2) · Canada (2) · Greece (2) · Italy (2) · Spain (2) · United Kingdom (2) · Iceland (1) · Switzerland (1)
Gunjan Shah (1) · Heather Landau, MD (1) · Murielle Roussel, MD (1) · Rajshekhar Chakraborty, MD (1)
2023 (3), 2025 (1)